Journal Article Summary
The article investigates how tenidap sodium, a medication, affects the way the body processes a combined oral contraceptive called Microgynon 30®. This topic is important because understanding drug interactions is crucial for ensuring the effectiveness of contraceptives and the safety of patients taking multiple medications. With many women using oral contraceptives, knowing whether other drugs influence their effectiveness can help prevent unintended pregnancies and ensure proper healthcare management.
In this study, 18 healthy premenopausal women participated in a double-blind, cross-over trial over two menstrual cycles. Each participant received either tenidap or a placebo for 11 days, starting shortly after menstruation, and then took Microgynon 30® on the 10th day of tenidap treatment. The researchers measured key pharmacokinetic parameters, such as the maximum concentration of the contraceptive hormones in the blood and the time it took to reach that concentration. The findings showed that tenidap did not significantly alter the pharmacokinetics of either levonorgestrel or ethinyloestradiol, the active ingredients in Microgynon 30®, indicating that the contraceptive remains effective when taken with tenidap.
Despite the positive results, the study has limitations, including a small sample size and a specific population of healthy women, which may not represent all users of oral contraceptives. Additionally, while no significant side effects were reported, it is essential for patients to discuss any medications they are taking with their healthcare providers. This conversation is crucial for ensuring safety and effectiveness, especially for women who may be prescribed tenidap or other medications while using oral contraceptives.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Coates P. E., Mesure R.. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive. British Journal of Clinical Pharmacology 1995. DOI: 10.1111/j.1365-2125.1995.tb04503.x. PMID: 7547095. PMCID: PMC1364937.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
